These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 26445325)

  • 41. Pachyonychia congenita responding favorably to a combination of surgical and medical therapies.
    Daroach M; Dogra S; Bhattacharjee R; Tp A; Smith F; Mahajan R
    Dermatol Ther; 2019 Sep; 32(5):e13045. PubMed ID: 31364784
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Keratin 16-null mice develop palmoplantar keratoderma, a hallmark feature of pachyonychia congenita and related disorders.
    Lessard JC; Coulombe PA
    J Invest Dermatol; 2012 May; 132(5):1384-91. PubMed ID: 22336941
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A novel frameshift mutation in keratin 16 underlies pachyonychia congenita with focal palmoplantar keratoderma.
    Cao LH; Luo Y; Wen W; Liu WL; Jiang L; Chen C; Ji CY; Zhang X
    Br J Dermatol; 2011 Nov; 165(5):1145-7. PubMed ID: 21668426
    [No Abstract]   [Full Text] [Related]  

  • 44. Symptomatic mucosal involvement in pachyonychia congenita: challenges in infants and young children.
    Goldberg I; Mashiah J; Kutz A; Derowe A; Warshauer E; Schwartz ME; Smith F; Sprecher E; Hansen CD
    Br J Dermatol; 2020 Mar; 182(3):708-713. PubMed ID: 31777952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. KERATIN 17-related recessive atypical pachyonychia congenita with variable hair and tooth anomalies.
    Koprulu M; Naeem M; Nalbant G; Shabbir RMK; Mahmood T; Huma Z; Malik S; Tolun A
    Eur J Hum Genet; 2022 Nov; 30(11):1292-1296. PubMed ID: 35676340
    [TBL] [Abstract][Full Text] [Related]  

  • 46. EGFR Signaling Is Overactive in Pachyonychia Congenita: Effective Treatment with Oral Erlotinib.
    Basset J; Marchal L; Hovnanian A
    J Invest Dermatol; 2023 Feb; 143(2):294-304.e8. PubMed ID: 36116508
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pachyonychia congenita: a case report.
    Kohli N
    Cutis; 2009 Nov; 84(5):269-71. PubMed ID: 20099620
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pachyonychia congenita type 2 (Jackson-Lawler syndrome) or PC-17: case report.
    Morais P; Peralta L; Loureiro M; Coelho S
    Acta Dermatovenerol Croat; 2013; 21(1):48-51. PubMed ID: 23683487
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The histopathological features of the nail plate in pachyonychia congenita.
    Stewart CL; Takeshita J; Hansen CD; Rubin AI
    J Cutan Pathol; 2020 Apr; 47(4):357-362. PubMed ID: 31845382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pachyonychia congenita tarda affecting only the nails.
    Vaccaro M; Guarneri F; Barbuzza O; Guarneri C
    Dermatol Online J; 2008 Feb; 14(2):12. PubMed ID: 18700115
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Rapamycin selectively inhibits expression of an inducible keratin (K6a) in human keratinocytes and improves symptoms in pachyonychia congenita patients.
    Hickerson RP; Leake D; Pho LN; Leachman SA; Kaspar RL
    J Dermatol Sci; 2009 Nov; 56(2):82-8. PubMed ID: 19699613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Botulinum toxin in disabling dermatological diseases].
    Messikh R; Atallah L; Aubin F; Humbert P
    Ann Dermatol Venereol; 2009 May; 136 Suppl 4():S129-36. PubMed ID: 19576479
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Sexual Dimorphism in Response to an NRF2 Inducer in a Model for Pachyonychia Congenita.
    Kerns ML; Hakim JMC; Zieman A; Lu RG; Coulombe PA
    J Invest Dermatol; 2018 May; 138(5):1094-1100. PubMed ID: 29277538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The molecular genetic analysis of the expanding pachyonychia congenita case collection.
    Wilson NJ; O'Toole EA; Milstone LM; Hansen CD; Shepherd AA; Al-Asadi E; Schwartz ME; McLean WH; Sprecher E; Smith FJ
    Br J Dermatol; 2014 Aug; 171(2):343-55. PubMed ID: 24611874
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pachyonychia congenita patients with mutations in KRT6A have more extensive disease compared with patients who have mutations in KRT16.
    Spaunhurst KM; Hogendorf AM; Smith FJ; Lingala B; Schwartz ME; Cywinska-Bernas A; Zeman KJ; Tang JY
    Br J Dermatol; 2012 Apr; 166(4):875-8. PubMed ID: 22098151
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gene expression profiling in pachyonychia congenita skin.
    Cao YA; Hickerson RP; Seegmiller BL; Grapov D; Gross MM; Bessette MR; Phinney BS; Flores MA; Speaker TJ; Vermeulen A; Bravo AA; Bruckner AL; Milstone LM; Schwartz ME; Rice RH; Kaspar RL
    J Dermatol Sci; 2015 Mar; 77(3):156-65. PubMed ID: 25656049
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Keratin K6c mutations cause focal palmoplantar keratoderma.
    Wilson NJ; Messenger AG; Leachman SA; O'Toole EA; Lane EB; McLean WH; Smith FJ
    J Invest Dermatol; 2010 Feb; 130(2):425-9. PubMed ID: 19609311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mutation of a type II keratin gene (K6a) in pachyonychia congenita.
    Bowden PE; Haley JL; Kansky A; Rothnagel JA; Jones DO; Turner RJ
    Nat Genet; 1995 Jul; 10(3):363-5. PubMed ID: 7545493
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Morphological and genetic analysis of steatocystoma multiplex in an Asian family with pachyonychia congenita type 2 harbouring a KRT17 missense mutation.
    Kanda M; Natsuga K; Nishie W; Akiyama M; Nagasaki A; Shimizu T; Shimizu H
    Br J Dermatol; 2009 Feb; 160(2):465-8. PubMed ID: 19120334
    [No Abstract]   [Full Text] [Related]  

  • 60. A novel H1 mutation in keratin 6a in an infant with pachyonychia congenita.
    Luo S; Luo Q; Zhang H; Wan C
    Indian J Dermatol Venereol Leprol; 2015; 81(4):385-7. PubMed ID: 26087092
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.